Condition

Stage II Multiple Myeloma

ClinicalTrials.gov condition label

Clinical trials7

Recruiting0

Common interventions15

Lead sponsors shown4

Clinical trials

7 shown

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesNCT01273766 · 2011-01-01

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadNCT01159067 · 2010-07-01

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantNCT00795769 · 2008-08-08

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantNCT00408681 · 2006-06-01

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaNCT00112723 · 2005-12-01

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerNCT00060372 · 2003-04-01

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerNCT00112593 · 1999-11-01

Common interventions

laboratory biomarker analysisOTHER3 deferasiroxDRUG2 alvocidibDRUG1 cyclosporineDRUG1 enzyme-linked immunosorbent assayOTHER1 fludarabine phosphateDRUG1 ipilimumabDRUG1 lithium carbonateDRUG1 management of therapy complicationsPROCEDURE1 mycophenolate mofetilDRUG1 ondansetronDRUG1 peripheral blood stem cell transplantationPROCEDURE1 survey administrationOTHER1 therapeutic allogeneic lymphocytesDRUG1 total-body irradiationRADIATION1

Leading sponsors

Fred Hutchinson Cancer Center3 National Cancer Institute (NCI)2 City of Hope Medical Center1 Wake Forest University Health Sciences1

Trial status mix

COMPLETED5

TERMINATED2

Phase mix

PHASE24

NA2

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.